E AND B TECHNOLOGIES, LLC — Department of Health and Human Services SBIR Phase I: N

Description

DESCRIPTION provided by applicant Novel caveolin modulators as therapeutics for uveitis Project Summary This research proposal seeks to develop a novel therapy for uveitis based upon modulation of inflammatory signaling via caveolae Uveitis drives of blindness affecting people of working age and producing significant disability in patients with chronic disease Caveolin modulators such as cavtratin are known to be able to modulate inflammatory signaling including edema and leukocyte migration key elements of the pathogenic cascade in uveitis Eandamp B Technologies is developing an improved second generation cavtratin CVX for the treatment of uveitis The project goal is to demonstrate that CVX can prevent retinal inflammation in mouse and rabbit models of uveitis and in phase II IND enabling work completed Longer term proof of concept in human clinical testing will be pursued and the clinical trials needed for regulatory approval will be conducted Successful completion of this project will establish a new therapeutic option for uveitis sufferers with a reduction in blindness and visual impairment PUBLIC HEALTH RELEVANCE Novel caveolin modulators as therapeutics for uveitis Project Narrative This research seeks to develop a treatment for uveitis a difficult to treat condition tht drives of blindness Because uveitis often affects people at working age it can cause significant disability A treatment for uveitis that both improves visual function and reduces the burden of treatment would improve the lives of patients